BUZ INVESTORS POTN High Quality Cannabis Extracts Cannabinoids and CBD Extracts continue to be a strong focal point for cannabis operators as revenues climb higher behind a robust jump in sales volume.

PotNetwork Holding, Inc. (POTN) Enters Partnership with Lawrence Taylor, Legendary NFL Football Star

PotNetwork Holding, Inc. Enters Partnership with Lawrence Taylor, Legendary NFL Football Star, for the Launch of Diamond CBD’s Exclusive LT Master Pain CBD Line

BUZ INVESTORS POTN High Quality Cannabis Extracts Cannabinoids and CBD Extracts continue to be a strong focal point for cannabis operators as revenues climb higher behind a robust jump in sales volume.

FOREX INVESTORS  PRESS RELEASE   PotNetwork Holding, Inc. (OTC Pink: POTN) (“Company”) is excited to announce that the Company has entered into a Joint Venture with Lawrence Taylor for the development and launch of the “LT Master Pain” Premium Line of CBD oils, a premium quality selection of products, designed to bring athletes and consumers a beneficial supplement to aid in pain relief, neurological support, and overall well-being.

“I am a firm believer in the vast range of beneficial attributes that CBD delivers for joint pain and headaches. Since I have incorporated CBD to my daily supplements, even I have been taken aback by the positive impact it has had on my overall quality of life. Upon thorough research, I have selected Diamond CBD to brand this new line because genuine potency is key for maximum effectiveness. I look forward to how this line will help pain sufferers everywhere,” stated Lawrence Taylor, former NFL NY Giants Hall of Fame linebacker.

Lawrence Taylor is among numerous NFL players that are believed to be experiencing debilitating headaches, one of the long-term effects of chronic traumatic encephalopathy (CTE). In addition to studies that show CBD’s effects on bodily pain management, it has been discovered that active compounds in cannabis, psychoactive tetrahydrocannabinol (THC) and non-psychoactive cannabidiol (CBD) engage the endocannabinoid system, providing them therapeutic effects. The endocannabinoid system (ECS) also plays a key role in managing memory, mood, cognition, and risk and reward. The ECS is the largest neurotransmitter system in the body. Studies on the beneficial attributes of CBD for CTE continue since the effects appear to impact the same regions of the brain. Degenerative CTE can lead to memory loss, confusion, impaired judgment, impulse control problems, aggression, depression and, eventually, progressive dementia.



PotNetwork Holding

 

According to studies summarized by the US National Library of Medicine National Institutes of Health, it has possible therapeutic effects over a broad range of neuropsychiatric disorders. CBD attenuates brain damage associated with neurodegenerative and/or ischemic conditions. It also has positive effects on attenuating psychotic, anxiety and depressive-like behaviors. Moreover, CBD affects synaptic plasticity and facilitates neurogenesis. The mechanisms of these effects are still not entirely clear, but seem to involve multiple pharmacological targets.

According to a report on CBS News, scientists with the Department of Veterans Affairs and Boston University, where the nation’s largest brain bank focused on the study of traumatic head injury is located, told PBS’s Frontline that 96 percent of the NFL players they have examined tested positive for chronic traumatic encephalopathy (CTE).

Lawrence Julius Taylor (born February 4, 1959), nicknamed “L.T.”, is a Hall of Fame former American football player. Taylor played his entire professional career as a linebacker for the New York Giants (1981–1993) in the National Football League (NFL). He is considered one of the greatest players in the history of football, and has been ranked as the greatest defensive player in league history by former players, coaches, media members, and news outlets such as the NFL Network and Sporting News. Taylor, retired in 1993, played 13 seasons with the New York Giants, helping the team win Super Bowl titles in 1987 and 1991.

During Taylor’s illustrious career, he revolutionalized the linebacker position in the game. His taunting, menacing upright rushing stance is the signature look for the new LT Pain Master CBD product line. As he changed the position forever, he hopes that his product line will likewise provide positive changes for those in need as well.

About PotNetwork Holding, Inc.: PotNetwork Holding, Inc. (OTC Pink: POTN) is a publicly traded holding company focused on investments in the development, production and marketing of products and services that serve the MJ industry and its various market segments. Its subsidiary, First Capital Venture Co., owns Diamond CBD, Inc., a leading maker of an extensive line of cutting-edge products containing hemp-extracted CBD oil.

About Diamond CBD, Inc.: Diamond CBD focuses on the research, development, and multi-national marketing of premium products based on hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD’s team consists of hemp industry pioneers and natural product experts, chemists, and scientists, dedicated to producing the finest and purest cannabidiol (CBD) oils. The result is a broad, robust selection of consumer products considered among the most powerful natural CBD oils, E-Liquids and related products found anywhere. For more information, please visit its website at www.DiamondCBD.com.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



 International Consolidated Companies, Inc. (INCC) announced today it entered into an exclusive license agreement with CBD Medicinals,

International Consolidated Companies, Inc. (INCC) Enters Into an Exclusive License Agreement for a CBD

INCC Enters Into an Exclusive License Agreement for a CBD Formulation Focused on Enhancing Cognitive Function in Adults

 

BUZ INVESTORS  PRESS RELEASE  International Consolidated Companies, Inc. (INCC) announced today it entered into an exclusive license agreement with CBD Medicinals, LLC for a patent application and trade secrets surrounding the development of an over the counter cannabidiol (CBD) formulation to improve cognitive function in adults.

This technology included novel combinations of CBD, mushroom derived hericenones, and neurotransmitter precursors. Both hericenones and CBD are known to have neuro-protective and neuro-regenerative effects in vivo.

“This will allow us to develop designer CBD products focused on niche markets where the demand is high,” said Antonio Uccello, President INCC.

International Consolidated Companies (INCC) was founded in 2002. INCC is focused on acquiring and producing innovative, high quality, and cost-efficient cannabis technologies.




 International Consolidated Companies

Forward-looking disclaimer

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risk and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements to be materially different from the statements made herein.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




BUZ INVESTORS PRESS RELEASE Comprehensive Amendment Agreements Tauriga Sciences Inc. ( OTC PINK : (TAUG ) (“Tauriga” or “the Company”),

$TAUG Enters into Three Comprehensive Amendment Agreements

|Chart | Calendar   | TRADE NOW | CANNABIS

Tauriga Sciences Inc. Enters into Three Comprehensive Amendment Agreements with Existing Debt Holder Group 10 Holdings LLC

BUZ INVESTORS  PRESS RELEASE Comprehensive Amendment Agreements  Tauriga Sciences Inc. OTC PINK : (TAUG ) “Tauriga” or “the Company”, a Company engaged in the building of businesses in the life sciences space, has today announced the execution of three comprehensive amendment agreements that directly correspond to the three distinct convertible debentures currently held by Group 10 Holdings LLC (“Group 10″). These three referenced outstanding debentures include: July 14, 2015 Debenture, August 3, 2016 Debenture, and March 31, 2017 Debenture. These amendment agreements were negotiated with Group 10 to address various default and penalty clauses that had the potential to result in massive future dilution and indebtedness. The Company firmly believes that the vast majority of recent dilution is attributable to the malpractice and subsequent conduct committed by its predecessor audit firm Cowan Gunteski & Co. P.A. (“Cowan Gunteski”).
The result of this malpractice was Tauriga’s inability to file its Fiscal Year 2015 Form 10-K (“Annual Report”) during late July 2015 and its subsequent delisting from the OTCQB Exchange on July 31, 2015; these events triggered the defaults and penalties that have affected the Company ever since (specifically in reference to the Union Capital $104,000 Note of May 28, 2015 and the Group 10 $96,000 Note of July 14, 2015). The Company is awaiting the assignment of the Trial date from the New Jersey Federal District Court (Trenton, New Jersey); the next Scheduled Court Date is set for May 23, 2017. The Company has previously disclosed that it is seeking monetary damages at Trial, in excess of $4,500,000 USD.

Comprehensive Amendment Agreements

In executing these amendment agreements with Group 10, the Company has successfully addressed the most urgent and critical issues and as a result, has strengthened its investor profile and capital structure. The Company has specifically addressed the following issues: the Conversion price(s) and term(s) (“conversion terms”), most favored Nation status (“favored Nation”), prohibitions against the Company securing other debt instruments (“permitted indebtedness”), and prohibitions against the Company entering into transactions which create a lien on the Company’s assets (“permitted lien”). Most importantly, as long as the Company’s share price remains at a minimum of $0.001 and the Company’s market capitalization remains at a minimum of $1,000,000 USD, the 75% discount applied to Group 10 conversions (which contractually was enforceable once the Company’s share price closed below $0.002), shall no longer apply. The other above mentioned issues/terms have been wholly forfeited by Group 10.

Tauriga’s Chief Executive Officer, Mr. Seth M. Shaw expressed, “The Company is pleased to have entered into these amendment agreements and appreciates the significant concessions agreed upon by Group 10. The Company believes that it has enhanced its ability to continue to fund its ongoing operations. Lastly, management wishes to reaffirm to shareholders its unwavering commitments to both make it to the finish line and build a successful future — long term.”

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. ( OTC PINK : TAUG ) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company’s previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it’s seeking monetary damages in excess of $4,500,000 USD.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare: OTCPK:(CTTC), OTCPK:(CAPS), OTCPK:(GOVX), OTCPK:(LCAR), OTCPK:(HDVY), OTCPK:(CRXM), OTCPK:(ICOTF), AMEX:(APHB), OTCPK:(FPMI), OTCPK:(BTHE), OTCPK:(ENTB), OTCPK:(CTBO), OTCPK:(TIKRF), OTCPK:(ADYNF), OTCPK:(PRTT), OTCPK:(ARNI), OTCPK:(OPLI), OTCPK:(ETBI,) OTCPK:(TLOG), OTCPK:(ERGO) » details
Headquarter Location: USA

Tauriga Sciences Inc is a biotechnology company. It is engaged in the development of proprietary drug compounds and medical devices.

Tauriga Sciences Inc formerly Immunovative, Inc., is a Florida corporation formed on April 8, 2001.The Company is a biotechnology company that is engaged in the development of proprietary drug compounds and medical devices.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

Buz Investors Canopy Growth Added to S&P/TSX - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") today announced that by being added to the S&P/TSX Composite Index,

Canopy Growth Corporation Enters Into An Agreement with Invictus MD’s AB Laboratories For Cannabis Sales

Canopy Growth Corporation Enters Into An Agreement with Invictus MD’s AB Laboratories For Cannabis Sales

 

BUZ INVESTORS Canopy Growth Corporation INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that AB Laboratories Inc.

BUZ INVESTORS  Canopy Growth Corporation  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), will provide their unique products in Canopy Growth Corporation’s (TSX:WEED) (“Canopy Growth”) curated CraftGrow line on Tweed Main Street’s online store, that brings high quality cannabis grown by a diverse set of producers. People want variety, they want different choices, and Tweed Main Street is an opportunity in the legal market where patients can see what is available through the convenience of an online store.

“AB Labs has received a number of direct inquiries from patients, which underscores the continuously growing demand. As a newer licensed producer with a market capitalization less than our peers, we are able to utilize Canopy Growth’s Tweed Main Street, giving us immediate access to the largest customer base in the rapidly expanding medical cannabis market.” said Dan Kriznic, Chairman and CEO of Invictus MD.  “Our collaboration with Canopy Growth demonstrates our commitment to making the sector strong and helping to expose medical cannabis patients visiting Tweed Main Street, to another high quality, unique brand.”




Canopy Growth Corporation

With Canada on the global stage as it moves closer to making history by being the first G-7 nation to legalize and regulate access to cannabis for the recreational market and the expected demand that will result, Invictus MD will continue to focus on building out AB Labs and AB Ventures Inc.’s (“AB Ventures”) production capacity in Ontario and successfully acquiring Acreage Pharms Ltd.’s (“Acreage Pharms”) production facility in Alberta.  After the successful development and acquisition of these facilities, Invictus MD anticipates that it will have the capacity to supply more than 50,000 kg of cannabis by 2020. This creates an attractive value proposition in the burgeoning cannabis market.

AB Labs, which maintains a 16,000 square foot facility located near Hamilton, Ontario, has successfully conducted test crops and is currently operating at half capacity, with full production capacity scheduled by the end of May 2017.  AB Ventures Inc.’s (“AB Ventures”), a company formed to develop a second licensed expansion facility through it’s common ownership with AB Labs, is expected to close a 100-acre acquisition on May 1, 2017, and if licensed under the ACMPR, construction of production facilities totaling 250,000 square feet will begin and be used for future cannabis cultivation. With licensing in place as expected, production at AB Ventures is anticipated to start as early as December 2017.

Considering the magnitude of AB Ventures’ land acquisition and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted, Invictus MD anticipates the combined production capacity of both AB Labs and AB Ventures to exceed 25,000 kilograms in 2020.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd
.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




BUZINVESTORS Introducing Simplicity to Cryptocurrencies – The Singapore-based ‘Crypto-One-Stop-Solution platform’ (COSS) has announced the beta release of its cryptocurrency services. The cryptocurrency

COSS.IO: Introducing Simplicity to Cryptocurrencies Enters Beta Phase

COSS.IO platform’s beta launch includes e-wallets, professional exchange and merchant platform services, brings cryptocurrency to all.

BUZINVESTORS Introducing Simplicity to Cryptocurrencies – The Singapore-based ‘Crypto-One-Stop-Solution platform’ <span data-recalc-dims=(COSS) has announced the beta release of its cryptocurrency services. The cryptocurrency " width="300" height="180" srcset="https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/04/Bitcoin-PR-Buzz-COSS.IO_-1.jpg?resize=300%2C180 300w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/04/Bitcoin-PR-Buzz-COSS.IO_-1.jpg?resize=768%2C461 768w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/04/Bitcoin-PR-Buzz-COSS.IO_-1.jpg?w=1000 1000w" sizes="(max-width: 300px) 100vw, 300px" />

BUZINVESTORS Introducing Simplicity to Cryptocurrencies – The Singapore-based ‘Crypto-One-Stop-Solution platform’ (COSS) has announced the beta release of its cryptocurrency services. The cryptocurrency solutions platform brings together a dedicated wallet service, exchange, and a merchant platform upon which cryptocurrency enthusiasts and investors can interact, trade currencies and ideas.

The COSS project is developed by an international team headquartered in Singapore under C.O.S.S. PTE LTD license and guided by the company’s CEO Rune Evensen. The COSS initiative was first presented by Rune to the MIT Fintech course committee in early 2016, and it’s due to the continued support and belief of the participants of the course that such a massive project was able to come to fruition.

After the course, the COSS team devised a detailed strategy, highlighting plans to initiate the project by December 2016, to be followed shortly by the Beta phase in early Q1, 2017. COSS has been dubbed ‘the living project’ by its developers and is designed with the intention of creating a self-sustaining ecosystem that can continue supporting more and more start-ups over time until the end of the internet itself.



OTHER STORIES BUZ TRADERS FOLLOW

Introducing Simplicity to Cryptocurrencies 

In February 2017, the platform published its whitepaper on COSS.IO homepage, outlining the technical specifications of the platform. COSS developers, learning from the past errors of Bitcoin developers have focused on the security of the platform, implementing the more consolidated, cryptocurrency-agnostic platform for the benefit of crypto-community and others.

The main purpose of COSS is to create a single, user-friendly ecosystem suitable for mass adoption among non-technical users, or individuals new to the Industry. The platform enables a system that combines cryptocurrency and fiat services, made available to customers over a single registered account within the platform.

The CEO of COSS Rune Evensen sharing thoughts about the platform’s focus said,

“Redefining simplicity has been on our mind since day one, and we truly believe that COSS can make it a lot simpler for any average Joe out there to enter the world of cryptocurrencies and blockchain-related products and services.”

The beta soft launch version of COSS platform has enabled its exchange feature with fully operational payment gateway (POS) system. Interested users can now test the exchange, merchant list and point-of-sale to get a feel of COSS platform and realize its vision. The cryptocurrency platform’s other main features, including a crowdfunding tool, an ICO platform, third-party plugins, market cap and coin overviews, a blockchain forum, remittance and payment gateway are all just around the corner awaiting implementation.

The native currency of the COSS platform, VEROS is implemented as an Ethereum smart contract, which governs the validation, distribution, value and the ownership of the tokens. Apart from VEROS, the platform will support most widely-used cryptocurrencies, enabling customers to convert them into fiat via the COSS exchange service. A lot more features will be added to the platform during the next phase of development.

On the event of COSS platform’s beta launch, Rune personally thanking every developer, community member, and supporter said,

“I would like to personally thank all the involved parties that have contributed endless hours to this project. Although we are just getting started, it is a huge MILESTONE for us to finally go live.”

About COSS.IO

COSS stands for Crypto-One-Stop-Solution and represents a platform which encompasses all features of a digital economic system based on cryptocurrency. The COSS system consists of website payments, seller tools, a marketplace, financial module, e-wallets, coin facilities and a mobile platform. The platform unifies the most popular crypto and fiat currency services, e.g. exchanges, payrolls, wallets, acquisitions and transactions.


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




TECHNICAL ANALYSIS – GOLD BULLISH AS IT ENTERS THE CLOUD; RECORDS 2-MONTH HIGH

TECHNICAL ANALYSIS – GOLD BULLISH AS IT ENTERS THE CLOUD; RECORDS 2-MONTH HIGH

TECHNICAL ANALYSIS – GOLD BULLISH AS IT ENTERS THE CLOUD; RECORDS 2-MONTH HIGH

shadow

Gold is posting some gains during today’s session so far, at one point rising above 1219 recording a 2-month high. Should it close higher, it will mark the 10th trading day of gains out of the last 11.

Delving into the Ichimoku analysis, the Tenkan-sen line (red) has crossed above the Kijun-sen (blue) in the beginning of January. This alignment is a bullish short-term signal. The bullish short-term momentum is reinforced by the RSI indicator which is at 66, well above the 50 threshold that separates bullish from bearish market sentiment (note though that it is fairly close to the 70 overbought level).

Continuing with the Ichimoku, prices have recently entered the cloud. Should they exit it from above, we would expect a continuation of the uptrend. However, if they exit it from below, a change in momentum is to be expected.

The 1220 key-level is likely to provide some resistance to upside moves. Should the price close above this level, the cloud top at around 1230 will come into view as another resistance point.

On the downside, the cloud bottom which coincides with the 1200 psychological level is expected to act as support (this is roughly the level of the Tenkan-sen line as well). Should this mark be challenged, it will bring into scope the 50-day moving average (MA) at 1178.05 as another important support point.

Looking at the bigger picture, despite a bearish cross being recorded in November with the 50-day MA moving below the 200-day one, price action since then has challenged the strength of this signal setting a more neutral medium-term outlook.

Featured Video Play Icon

$KSIX Media Holdings Enters Into Letter-of-Intent to Acquire True Wireless, LLC.

KSIX Media Holdings Enters Into Letter-of-Intent to Acquire True Wireless, LLC.

KSIX Media Holdings Enters Into Letter-of-Intent to Acquire True Wireless, LLC.

LAS VEGAS, NV–(Marketwired – Oct 26, 2016) – KSIX Media Holdings, Inc. (“KSIX” and/or “Company”) (OTC PINK: KSIX), a Las Vegas, Nevada-based publicly traded company under the ticker symbol KSIX on the OTC, has entered into a Letter of Intent (the “LOI”) for a $24 million acquisition of telecommunications company True Wireless, LLC — an Oklahoma Limited Liability Company. The LOI in connection with the proposed acquisition includes all the assets of True Wireless, LLC.

“We are excited about the opportunities presented by combining the assets and operations of True Wireless with the capabilities of KSIX,” said Carter Matzinger, CEO of KSIX. “True Wireless is a current client of ours and we believe it’s a fantastic acquisition. Together we’ll be able to capture multiple revenue synergies and significantly expand the True Wireless subscriber base. Taking our talents and marketing our own asset is an exciting development for Ksix. We have always been marketing other companies’ services and now it’s time for us to market our own company. Our ultimate goal is to become one of the leading Lifeline providers in the US, and the first and only 100% automated and completely online compliant Lifeline provider.”




Other Stories Buz Traders Follow

KSIX Media Holdings

The transaction features an investment structure and set of terms that offer the current equity owners an opportunity to realize immediate liquidity as well as allow existing management a meaningful opportunity to participate the upside potential of the new combined entity.

Based on True Wireless trailing nine-month revenues of approximately $8.75 million and net income of approximately $2.4 million during the same period. KSIX will assume all debts and all existing contingent liabilities. The tentative deal terms are made up of three components:

1) Cash payment of up to $6 million through a debt instrument
2) A promissory note of $6 million
3) The issuance of common stock in KSIX totaling 24 million of shares of common stock.

Following the closing of this transaction, KSIX intends to fully integrate the management of True Wireless and keep the company as a wholly owned subsidiary going forward and will retain key True Wireless management positions. The new combined headquarters will operate out of the existing KSIX facility in Las Vegas, NV. The management anticipates having approximately 75 million shares outstanding post close of the transaction.

ABOUT KSIX MEDIA HOLDINGS
KSIX Media Holdings, Inc. (OTC PINK: KSIX) is an SEC fully reporting media and Internet company located in Las Vegas, Nevada. Currently, there are three divisions, KSIX, LLC, DigitizeIQ, LLC and Blvd Media Group, LLC, and KSIX, LLC is a digital advertising network utilizing proprietary technology and intellectual properties designed to create revenue streams for their affiliate clients and to provide advertisers with increased measurable audience. KSIX provides performance-based marketing solutions to drive traffic and conversions within a Cost-Per-Action (“CPA”) business model. KSIX has an online advertising network that works directly with advertisers and other networks to promote advertiser campaigns. KSIX manages offer tracking, reporting, and distribution on the third-party platform.

ABOUT TRUE WIRELESS
True Wireless is an eligible telecommunications carrier (“ETC”) providing discounted and subsidized wireless (cell phone) service. True Wireless was founded in 2008 to provide Lifeline assisted wireless services to eligible Americans in 5 states: Texas, Oklahoma, Arkansas, Maryland, and Rhode Island. True Wireless utilizes all 4 major wireless carrier networks to assist those who qualify for the Federal Lifeline Program. Customers are able to choose from a wide variety of phones.

Major Aerospace Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




$ZDPY Strengthens Balance Sheet, Enters 2017 in Strong Position

a) Pos(r)--md Pos(r)--sm W(1/1)--sm W(1/4) W(1/1)--md ie-7_Mstart(-310px)" data-reactid="24">
r) Bxz(bb) Fl(end) Fl(n)--sm Fl(n)--md M(a)--sm M(a)--md Maw(340px) Maw(640px)--sm Maw(640px)--md P(20px) Pb(0)--md Pb(0)--sm W(1/1)" data-reactid="27">
a) W(a)--sm W(0) W(a)--md" data-reactid="28">
r) Start(-150px) Start(a)--sm Start(a)--md W(a)--sm W(300px) W(a)--md" data-reactid="29">

36px) Fz(25px)--sm Fz(32px) Mb(17px)--sm Mb(20px) Mb(30px)--lg Ff($ff-primary) Lts($lspacing-md) Fw($fweight) Fsm($fsmoothing) Fsmw($fsmoothing) Fsmm($fsmoothing) Wow(bw)" data-reactid="3">Zoned Properties Strengthens Balance Sheet, Enters 2017 in Strong Position for Sustainable Growth

Zoned Properties Strengthens Balance Sheet, Enters 2017 in Strong Position for Sustainable Growth
Zoned Properties, Inc. (ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries, including the licensed marijuana industry, today announced that it has taken proactive steps to strengthen the Company’s balance sheet.
bb) Mstart(0)--sm Mstart(0)--md Mstart(33.3%) P(20px) W(1/1)--sm W(1/1)--md ie-7_W(45%)" data-reactid="39">
r) M(a) Maw(600px) Maw(800px)--lg Mih(650px) Mih(0)--sm" data-reactid="40">
r) P(20px)--sm Pt(17px)--sm" data-reactid="2">
bw) Cl(start) Mb(20px) Ff($ff-secondary) Fz(15px) Lh(1.6)" data-reactid="4">

Specifically, the Company has:

    40px) Mt(1.5em) Mb(1.5em) List(d)" data-type="list" data-reactid="7">
  • Agreed to sell its property at 422 S. Madison Dr. in Tempe, Ariz. for $2.125 million in gross proceeds. This property is leased to a non-marijuana business, and management views it as non-core to the Company’s strategy. $20,000 has been placed into escrow. The sale is expected to close in approximately 60 days, following due diligence, enabling Zoned Properties to be released from the deed of trust related to the property.
  • Received aggregate commitments for $2.020 million in financing from the Company’s Chief Executive Officer and a private investor in the form of convertible debentures bearing an annual interest rate of 6% over a 5-year term. The additional capital will directly contribute to shovel-ready development and expansion plans at the Chino Valley, Arizona cultivation facilities and Tempe, Arizona Medical Marijuana Business Park.

“As we enter 2017, we are in the strongest position in our company’s history, with a streamlined balance sheet, improving access to growth capital and a portfolio of properties well-situated to benefit from the continuing expansion of the licensed marijuana industry,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties. “During 2016, we cleared the path to expand our properties in Tempe and Chino Valley, Arizona, as well as Parachute, Colorado, and we look forward to completing these expansions and securing additional tenants during 2017. We have expanded and strengthened our board of directors, and established an independent audit committee. Our sustainable approach to property development and risk mitigation is resonating with municipalities and tenants, and I am increasingly confident regarding the Company’s ability to execute its business development strategy. The financial investment made by our largest shareholder has reinforced the strong commitment our shareholders have to the Company and demonstrates the value of the progress we have made to date and our business plans and growth potential going forward.”

“We expect to utilize the proceeds from the property sale and the additional financing to retire a majority of the Company’s debt, including the deed of trust and existing convertible debt. We also plan to complete the next phases of expansion for the tenants at our key licensed marijuana properties, enabling us to generate higher rental revenue and driving sustainable property value,” added Mr. McLaren. “With additional cash on hand and an improved balance sheet we are well-positioned to selectively make additional investments to fuel our growth objectives for the upcoming year.”

About Zoned Properties, Inc. (ZDPY):

Zoned Properties is a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries. The Company acquires commercial properties that face unique zoning challenges and identifies solutions that can potentially have a major impact on the cash flow and value generated. Zoned Properties targets commercial properties that can be acquired and potentially re-zoned for specific purposes. Zoned Properties does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substances Act.

Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Sarepta Therapeutics, Inc. SRPT NASDAQ

Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program

Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program

Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program

License Agreement  Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered an exclusive license agreement with Nationwide Children’s Hospital, for their Galgt2 gene therapy program developed by researcher Dr. Paul Martin, Ph.D.

“We are taking a multi-front approach in the battle against Duchenne muscular dystrophy,” said Edward Kaye, Sarepta’s chief executive officer. “We find this therapeutic approach to be of particular interest as it has the potential to treat all patients suffering from the disease regardless their mutation.”

The experimental program explores the potential surrogate gene therapy approach to Duchenne muscular dystrophy. As a “surrogate gene therapy approach”, the gene therapy looks to induce genes that make proteins that can perform a similar function as dystrophin, with the goal of producing a muscle cell that can function normally even when dystrophin is absent. It has the potential to be used broadly in several muscular dystrophies.

“We are pleased to have this opportunity to help advance our Galgt2 gene therapy program,” said Dr. Kevin Flanigan, the Principal Investigator leading the clinical trial. “Our goal is to have this program in the clinic during 2017 and begin to evaluate a therapy that has the potential to treat patients of all ages and disease severity.”

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at www.sarepta.com.

About The Research Institute at Nationwide Children’s Hospital

Named to the Top 10 Honor Roll on U.S. News & World Report’s 2016-17 list of “America’s Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest not-for-profit freestanding pediatric healthcare systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children’s faculty train the next generation of pediatricians, scientists and pediatric specialists. The Research Institute at Nationwide Children’s Hospital is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities in the U.S., supporting basic, clinical, translational and health services research at Nationwide Children’s. The Research Institute encompasses three research facilities totaling 525,000 square feet dedicated to research. More information is available at NationwideChildrens.org/Research.Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )